CoChat

Effect of Donepezil on Cognition in Severe Alzheimer's Disease: A Pooled Data Analysis

Cummings, Jeffrey, Jones, Roy, Wilkinson, David, Lopez, Oscar, Gauthier, Serge, Waldemar, Gunhild, Zhang, Richard, Xu, Yikang, Sun, Yijun, Richardson, Sharon, Mackell, Joan · 2010 · Journal of Alzheimer's Disease
Cited by 36

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

To better characterize response to donepezil in patients with severe AD, Severe Impairment Battery (SIB) data were pooled from four donepezil clinical trials (N=904). Changes in SIB total and domain scores from baseline to week 24 were compared between placebo and donepezil treatment groups (observed case analysis). Analyses were stratified by baseline severity (Mini-Mental State Examination [MMSE] scores 1-5, 6-9, 10-12 and 13-17) to allow investigation of responses at different stages of cognitive impairment. Relationships to global and functional measures were explored. The difference between donepezil- and placebo-treated patients in least squares (LS) mean change in SIB total scores from baseline to week 24 was 6.22 (p < 0.0001, Cohen's d, 0.53). Treatment-placebo differences were statistically significant for each baseline severity stratum, being greatest for the MMSE 6-9 stratum (LS mean difference, 7.60; p < 0.0001, Cohen's d, 0.66). Treatment-placebo differences in LS mean change in SIB domain scores significantly favored donepezil for seven of nine domains (range, p = 0.0056 to p < 0.0001; Cohen's d, 0.17-0.48). Change in total SIB score correlated significantly with change in measures of activities of daily living and global status. These results indicate that donepezil provides cognitive benefits in patients with severe AD, including those most markedly impaired. The treatment effect size and correlation between improvements in SIB scores and functional and global outcome measures suggest the drug-placebo differences are clinically meaningful.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-2010-100078

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 36

Metadata

Authors
Cummings, J., Jones, R., Wilkinson, D., Lopez, O., Gauthier, S., Waldemar, G., Zhang, R., Xu, Y., Sun, Y., Richardson, S., & Mackell, J.
Venue
Journal of Alzheimer's Disease
Published
2010-09-02
Volume
21
Issue
3
Pages
843-851
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1481369052
Cited by
36
References
2
FWCI
2.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Donepezil on Cognition in Severe Alzheimer's Disease: A Pooled Data Analysis. https://app.cochat.ai/papers/10.3233/jad-2010-100078
The paper
Cummings, J., Jones, R., Wilkinson, D., Lopez, O., Gauthier, S., Waldemar, G., Zhang, R., Xu, Y., Sun, Y., Richardson, S., & Mackell, J. (2010). Effect of Donepezil on Cognition in Severe Alzheimer's Disease: A Pooled Data Analysis. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-100078

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.